We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy.
- Authors
Eibl, Nicole L.; Kopp, Hans-Peter; Nowak, Helga R.; Schnack, Christoph J.; Hopmeier, Pierre G.; Schernthaner, Guntram; Eibl, N L; Kopp, H P; Nowak, H R; Schnack, C J; Hopmeier, P G; Schernthaner, G
- Abstract
<bold>Objective: </bold>To investigate the effects of long-term high-dose oral magnesium (Mg) therapy (30 mmol/day) in patients with type II diabetes. Low plasma magnesium levels have been reported in type II diabetes and are associated with insulin resistance and diabetic late complications.<bold>Research Design and Methods: </bold>Forty patients with type II diabetes and hypomagnesemia were observed in a randomized double-blind placebo-controlled trial for 3 months (body mass index: 28 +/- 4 kg/m2; HbA1c: 7.4 +/- 0.8%). Plasma and urine magnesium and metabolic control parameters were determined, and side effects were considered, especially with regard to patients' compliance.<bold>Results: </bold>A significant increase in plasma magnesium levels was observed after 3 months of treatment (Mg: 0.73 +/- 0.8 vs. 0.81 +/- 0.1 mmol/l), reaching magnesium levels of the control group (0.88 +/- 0.8 mmol/l; NS); metabolic control, however, was not altered (HbA1c: 7.2 +/- 0.7 vs. 7.4 +/- 0.9%). Six months after the end of the trial, plasma magnesium declined to pretreatment levels (Mg: 0.73 +/- 0.07 mmol/l). The prevalence of side effects was high at the beginning and was reduced significantly during treatment.<bold>Conclusions: </bold>We conclude that oral magnesium replacement therapy corrects hypomagnesemia after a minimum treatment period of 3 months. These observations might be important for the prevention of diabetic late complications.
- Publication
Diabetes Care, 1995, Vol 18, Issue 2, p188
- ISSN
0149-5992
- Publication type
journal article
- DOI
10.2337/diacare.18.2.188